Inovio Pharmaceuticals has begun collaboration and sold the exclusive rights to an HPV types 16 and 18 vaccine to MedImmune, the biologics research and development arm of AstraZeneca, for $700 million, according to a press release.
“[The] collaboration with Inovio leverages our deep internal expertise in the use of vaccines to drive antigen-specific, T-cell responses,” David Berman, MD, PhD, senior vice president and head of MedImmune’s oncology medicine development unit, said in the release.